22. Januar 2016 von

German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation

DAIICHI SANKYO EUROPE GmbH: Munich (ots/PRNewswire) – Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the German public health agency, The Federal Joint Committee (Gemeinsamer Bundesausschuss – G-BA), has granted an indication of a minor additional …

Comments are closed.